| [1] |
WU Chunxiao, PANG Yi, GU Kai, YAN Jiaying, WANG Chunfang, XIANG Yongmei, SHI Yan.
Survival analysis of female breast cancer in Shanghai: a population-based study from 2002 to 2017
[J]. China Oncology, 2025, 35(3): 291-297.
|
| [2] |
WANG Ting, QIN Yi, XU Xiaowu, YU Xianjun.
New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024
[J]. China Oncology, 2025, 35(1): 1-11.
|
| [3] |
ZHANG Zhiyue, HE Huijing, SHAN Guangliang, LIN Yansong.
Research progress in epidemiology and risk factors of thyroid cancer
[J]. China Oncology, 2025, 35(1): 21-29.
|
| [4] |
Society of Neuroendocrine Neoplasm of China Anti-Cancer Association.
China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)
[J]. China Oncology, 2025, 35(1): 85-142.
|
| [5] |
WANG Shanshan, YE Dingwei, YANG Li, CHENG Fan, YANG Tiejun, ZHANG Xiaoping, YU Zhixian, ZHANG Qingyun, YANG Yong.
Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China
[J]. China Oncology, 2024, 34(11): 1011-1019.
|
| [6] |
LI Tianjiao, YE Longyun, JIN Kaizhou, WU Weiding, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023
[J]. China Oncology, 2024, 34(1): 1-12.
|
| [7] |
QU Ning, WANG Yuting, MA Ben, WANG Yu.
Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022
[J]. China Oncology, 2023, 33(5): 423-430.
|
| [8] |
PAN Jian, ZHU Yao, DAI Bo, YE Dingwei.
Advances in basic research, clinical diagnosis and treatment of prostate cancer in 2022
[J]. China Oncology, 2023, 33(3): 210-217.
|
| [9] |
LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie.
Updates on medical treatment for neuroendocrine neoplasm
[J]. China Oncology, 2022, 32(9): 757-764.
|
| [10] |
ZHENG Xiuli, YAO Zhiyuan, WU Mingli, ER Limian, LI Shengmian.
Analysis of risk factors of lymph node metastasis and comparison of endoscopic resection methods in rectal neuroendocrine neoplasm
[J]. China Oncology, 2022, 32(9): 800-806.
|
| [11] |
WU Jianhui, CHU Xiangling, WANG Liqiang, LIN Xinqing, XIE Xiaohong, XIE Mengqing, ZHAO Jing, DENG Haiyi, YANG Yilin, QIU Guihuan, ZHOU Maolin, SUN Ni, LI Ru, CHEN Ying, DENG Jiaxi, ZENG Chen, PAN Bolin, QIN Yinyin, LIU Ming, SU Chunxia, ZHOU Chengzhi.
Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer
[J]. China Oncology, 2022, 32(6): 469-477.
|
| [12] |
QI Mengfang, TIAN Tian, HUANG Rui.
Clinicopathological characteristics and 131I treatment of differentiated thyroid carcinoma in children and adolescents of different age groups
[J]. China Oncology, 2022, 32(5): 404-409.
|
| [13] |
ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021
[J]. China Oncology, 2022, 32(1): 1-12.
|
| [14] |
ZHANG Jinzhong , LI Yueqi , SHI Ke , YANG Liang , GUO Dan .
Expression and clinical significance of PLK4 gene in esophageal squamous cell carcinoma and its effect on cell proliferation, invasion and migration
[J]. China Oncology, 2021, 31(12): 1185-1193.
|
| [15] |
PAN Jian, WEI Yu, YE Dingwei, ZHU Yao.
Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2021, 31(11): 1104-1109.
|